Disitamab Vedotin
Gastroesophageal Junction Adenocarcinoma
BeOne Medicinesantibody_drug_conjugatePhase 2Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
109 Active assets in the Gastroesophageal Junction Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan AstraZeneca | Phase 3 | BBB |
Cyclophosphamide Beijing Biotech | Phase 3 | BB |
Pembrolizumab Eikon Therapeutics | Phase 3 | BB |
Fluorouracilum Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Oxaliplatin Alliance for Clinical Trials in Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Disitamab Vedotin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →